This review synthesizes evidence linking the bacteriome, mycobiome, and phageome to colorectal carcinogenesis, immune modulation, metabolic signaling, and therapeutic response and proposes that therapeutic resistance may sometimes reflect a treatment-selected ecological state rather than the action of a single resistance-conferring microbe.
Abstract
Colorectal cancer develops within a physiologically altered intestinal ecosystem. Epithelial barrier disruption, chronic inflammatory signaling, immune remodeling, and metabolic rewiring reshape host-microbial interactions in this niche. Although most colorectal cancer microbiome reviews have emphasized bacterial taxa, the gut ecosystem is inherently multi-kingdom, comprising bacteria, fungi, bacteriophages, and other viral elements that interact with one another and with the host. In this review, we propose that the clinically relevant unit of the colorectal cancer microbiome is often not a single organism but a configured interkingdom whose functional output depends on local physiology. Throughout, we distinguish human observational associations from mechanisms demonstrated in experimental models and from prospectively validated clinical effects. We synthesize evidence linking the bacteriome, mycobiome, and phageome to colorectal carcinogenesis, immune modulation, metabolic signaling, and therapeutic response. We highlight context-dependent mechanisms, including the paradoxical effects of Fusobacterium nucleatum, fungal regulation of myeloid and inflammasome pathways, phage-mediated control of bacterial virulence, and cross-kingdom metabolic circuits involving butyrate, succinate, bile acids, lactate, and arginine. We further propose, as a conceptual framework requiring longitudinal validation, that therapeutic resistance may sometimes reflect a treatment-selected ecological state rather than the action of a single resistance-conferring microbe. Finally, we address the reproducibility challenges raised by low-biomass intratumoral microbiome studies and outline minimum methodological standards for future multi-kingdom investigations. A framework centered in physiology, attentive to contamination, and organized around interactions may improve biomarker development and support rational microbiome-directed strategies in colorectal cancer.
This review critically examines emerging microbiome-directed strategies, including fecal microbiota transplantation, next-generation probiotics, defined bacterial consortia, dietary and perioperative interventions, postbiotics, and bacteriophage-based approaches, as potential means of modifying immune resistance in MSS...
Colorectal cancer (CRC) is a major global health burden, and chemotherapy resistance remains a major challenge to effective treatment. Increasing evidence indicates that the gut microbiota may contribute to variability in chemotherapy response in CRC through microbial metabolism, tumor-cell adaptation, immune regulatio...
Yan Li, Fang-Rui Wang, Tao Li et al.· Frontiers in Oncology· 0 citations
Current evidence linking the intestinal microbiome to anticancer therapy outcomes is synthesised, strategies and challenges for therapeutic modulation of the microbiome are evaluated, and emerging insights into the mycobiome are introduced.
A. Moradi, R. Winayak, S. Pal· The Lancet Oncology· 0 citations
Cancers develop within a host ecosystem in which kinds of factors such as gut and tumor‐resident microbiota influence the tumor microenvironment (TME) and therapeutic response. High‐throughput sequencing has revealed the presence of low‐biomass bacteria, fungi, and viruses across diverse malignancies, establishing the...
Juan Lu, Meng-Juan Xuan, Liang Yu et al.· MedComm· 0 citations
Ulcerative colitis (UC) is sustained by reciprocal interactions among intestinal dysbiosis, altered microbial metabolism, epithelial barrier dysfunction, and mucosal immune activation. This narrative review examines that microbiota–metabolism–barrier–immune network and evaluates how traditional Chinese medicine (TCM) m...
Jing Chen, Jing Du, Bao-Xi Mu et al.· Frontiers in Pharmacology· 0 citations
The gut microbiome is emerging as an important component of modern gastroenterology, with considerable potential for improving disease prevention, diagnosis, prognosis, and treatment.
Ulykbek Daurenov, Dana Suyunbay, Alua Toqseiıt et al.· European Open Science Space· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.